Literature DB >> 10781687

Amifostine cytotoxicity and induction of apoptosis in a human myelodysplastic cell line.

I Ribizzi1, J W Darnowski, F A Goulette, M R Sertoli, P Calabresi.   

Abstract

Amifostine (AMF), a phosphorylated aminothiol, has been used to treat myelodysplastic syndrome (MDS), where it produces a stimulatory effect on hematopoiesis in bone marrow. To determine if AMF also produced a direct effect on human MDS cells, we planned a study to evaluate the effect of a continuous exposure to AMF on a human MDS cell line. AMF was shown to have a growth-inhibitory effect on MDS cells, with an IC(50) of 14 microM after a 5 day exposure. Cell cycle analysis revealed that a 5 day exposure to 20 microM AMF increased the percentage of cells in G0/G1 and this was accompanied by a decrease in the percentage of cells in S phase. Cytoflorometric and agarose-gel electrophoretic analysis revealed that this effect correlated with cell membrane alterations and DNA fragmentation consistent with an induction of apoptosis without affecting the expression of p53 protein or inducing any lymphoid or myeloid differentiation in the MDS cell line. We conclude that the continuous exposure of a human MDS cell line to AMF is cytotoxic and associated with an induction of apoptosis independent of alterations in p53 expression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10781687     DOI: 10.1016/s0145-2126(00)00007-2

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  4 in total

Review 1.  Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.

Authors:  C R Culy; C M Spencer
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  The impact of redox and thiol status on the bone marrow: Pharmacological intervention strategies.

Authors:  Christina L Grek; Danyelle M Townsend; Kenneth D Tew
Journal:  Pharmacol Ther       Date:  2010-10-15       Impact factor: 12.310

3.  Amifostine does not protect thyroid cancer cells in DNA damaging in vitro models.

Authors:  Joanna Klubo-Gwiezdzinska; John Costello; Kirk Jensen; Aneeta Patel; Rok Tkavc; Douglas Van Nostrand; Kenneth D Burman; Leonard Wartofsky; Vasyl Vasko
Journal:  Endocr Connect       Date:  2017-08-08       Impact factor: 3.335

4.  The effect of amifostine on differentiation of the human megakaryoblastic Dami cell line.

Authors:  Hai-Tao Wang; Bo Yang; Bo Hu; Xiao-Hua Chi; Long-Long Luo; Hong-Qi Yang; Xiao-Ling Lang; Jing Geng; Chun-Xia Qiao; Yan Li; Xiao-Xiong Wu; Hong-Li Zhu; Ming Lv; Xue-Chun Lu
Journal:  Cancer Med       Date:  2016-05-26       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.